Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

Podobne zapisy

• Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
  od: Zeybek, Burak, i wsp.
  Wydane: (2020)
• Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
  od: Emanuele Perrone, i wsp.
  Wydane: (2020-02-01)
• Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
  od: Lopez, Salvatore, i wsp.
  Wydane: (2020)
• Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
  od: Emanuele Perrone, i wsp.
  Wydane: (2020-03-01)
• Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
  od: Perrone, Emanuele, i wsp.
  Wydane: (2020)